Paula Aristizabal, a pediatric oncologist at Rady Children’s Hospital-San Diego and associate professor of pediatrics in pediatric hematology/oncology at the University of California San Diego and Moores Cancer Center, received a $4 million R01 research grant to expand a pilot program aimed at improving diverse participation in pediatric cancer clinical trials.
In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.
